625446-51-7

Downstream Products

• 1026170-39-7 C₂₉H₃₅ClN₄O₄ 
• 1269149-58-7 6-{2-[3-chloro-4-(propan-2-yloxy)phenyl]ethyl}-6-cyclopentyl-4-hydroxy-3-methyl-5,6-dihydro-2H-pyran-2-one 
• 1269149-62-3 6-{2-[3-chloro-4-(propan-2-yloxy)phenyl]ethyl}-6-cyclopentyl-3-ethyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one 
• 1269149-64-5 6-{2-[3-chloro-4-(propan-2-yloxy)phenyl]ethyl}-6-cyclopentyl-4-hydroxy-3-propyl-5,6-dihydro-2H-pyran-2-one 
• 1269149-70-3 C₃₀H₃₅ClN₂O₄ 
• 1269149-65-6 6-{2-[3-chloro-4-(propan-2-yloxy)phenyl]ethyl}-6-cyclopentyl-4-hydroxy-3-(2-methylpropyl)-5,6-dihydro-2H-pyran-2-one 
• 1269149-69-0 6-{2-[3-chloro-4-(propan-2-yloxy)phenyl]ethyl}-6-cyclopentyl-4-hydroxy-3-(propan-2-yl)-5,6-dihydro-2H-pyran-2-one 
• 877132-44-0 6-[2-(3-chloro-4-isopropoxyphenyl)ethyl]-6-cyclopentyl-3-[(1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one 

Relevant academic research and scientific papers

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

Compounds of formula (I) are hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) inhibitors, and are useful in therapeutic and prophylactic treatment of persons infected with hepatitis C virus.